Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2025-12-08 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
募集资金管理制度（2025年12月）
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and is issued by 迈威（上海）生物科技股份有限公司. It details the rules, procedures, and controls regarding the management, storage, and use of funds raised by the company through stock issuance or other equity securities. It references regulatory requirements from Chinese securities laws and stock exchange rules, and includes detailed governance on the use, storage, and supervision of raised funds. The document is a policy or internal management system rather than a financial report, announcement, or regulatory filing. It does not contain financial statements, earnings data, voting results, or audit opinions. It is a governance or management internal control document related to capital management. Given the filing definitions, this document best fits under Capital/Financing Update (CAP) as it provides detailed updates and rules on the company's fundraising and capital usage management. The document length (6903 characters) and content confirm it is a substantive policy document rather than a brief announcement or certification. Therefore, the classification is CAP with high confidence.
2025-12-08 Chinese
迈威生物关于召开2025年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 third extraordinary general meeting of shareholders for a company, including details about the meeting date, voting methods, agenda items, and instructions for shareholders. It does not contain actual financial statements or results but is an announcement related to a shareholder meeting. The document length is 3451 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-12-08 Chinese
关联交易管理制度（2025年12月）
Governance Information Classification · 95% confidence The document is titled "关联交易管理制度" which translates to "Related Party Transaction Management System". It is a detailed internal policy document outlining the principles, scope, pricing, procedures, disclosure, and governance related to related party transactions for the company 迈威（上海）生物科技股份有限公司. The document references relevant laws and stock exchange rules, specifies the roles of directors and shareholders in approving related party transactions, and details disclosure requirements. It is a governance and compliance document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it a notice or announcement of a report. It is a governance-related internal rules document. Therefore, the most appropriate classification is Governance Information (CGR).
2025-12-08 Chinese
迈威生物关于以集中竞价交易方式回购股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about the progress of its share repurchase program, detailing the number of shares repurchased, the price range, and the total amount spent. It references specific board meetings approving the repurchase plan and adjustments to the repurchase price limits. The document does not contain financial statements or comprehensive financial data but focuses on the status and details of the share buyback activity. This fits the definition of a 'Transaction in Own Shares' filing, which reports on the company's buyback of its own shares.
2025-12-01 Chinese
迈威生物自愿披露关于9MW1911临床研究进展的公告
Regulatory Filings Classification · 90% confidence The document is a voluntary disclosure announcement by Maiwei (Shanghai) Biotech Co., Ltd. regarding the progress of clinical research for their drug 9MW1911. It provides detailed clinical trial results, including safety, efficacy, and ongoing study phases. The document is relatively short (1836 characters) and focuses on clinical trial progress and data rather than financial performance or regulatory filings. It is not an annual or interim financial report, audit report, or earnings release. It is also not a regulatory filing or report publication announcement since it contains substantive clinical data and risk disclosures. The content is a clinical research progress announcement, which does not fit into financial report categories but aligns best with Regulatory Filings (RNS) as a general announcement category for disclosures that do not fit other specific financial report types.
2025-11-30 Chinese
迈威生物第二届监事会第二十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board (监事会) of a company regarding the resolution passed in their meeting. It details the meeting's convening, attendance, and the approval of a proposal related to opening and changing special accounts for raised funds and signing regulatory agreements. The document references compliance with regulatory rules and states the voting results. It also points to a related announcement published on the stock exchange website for more details. The document is short (879 characters) and serves as an official announcement of a board resolution rather than a full report or financial statement. It is not an annual report, audit report, earnings release, or any detailed financial or management report. It is also not a proxy solicitation or voting result declaration. The content fits best with a Regulatory Filing (RNS) as it is a regulatory announcement about a board resolution and compliance with fundraising account management rules, without substantive financial data or detailed report content.
2025-11-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.